LivaNova (NASDAQ:LIVN) Cut to “Peer Perform” at Wolfe Research

Wolfe Research downgraded shares of LivaNova (NASDAQ:LIVN) from an outperform rating to a peer perform rating in a report published on Wednesday, MarketBeat.com reports.

Several other research firms have also weighed in on LIVN. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research note on Tuesday, January 28th. Robert W. Baird upped their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Mizuho dropped their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Finally, StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, LivaNova presently has an average rating of “Buy” and an average target price of $64.20.

LivaNova Stock Up 1.7 %

LIVN stock opened at $41.63 on Wednesday. LivaNova has a 52-week low of $40.37 and a 52-week high of $64.47. The company’s 50 day simple moving average is $47.40 and its 200-day simple moving average is $49.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a market capitalization of $2.26 billion, a P/E ratio of 99.12 and a beta of 1.00.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

Several large investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. bought a new stake in LivaNova in the fourth quarter worth approximately $4,812,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in LivaNova by 25.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock worth $7,107,000 after acquiring an additional 30,718 shares in the last quarter. Squarepoint Ops LLC grew its position in LivaNova by 74.3% in the fourth quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock worth $5,161,000 after acquiring an additional 47,494 shares in the last quarter. Two Sigma Advisers LP grew its position in LivaNova by 148.5% in the fourth quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock worth $9,936,000 after acquiring an additional 128,200 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of LivaNova by 27.2% during the 4th quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock worth $20,357,000 after buying an additional 93,985 shares during the period. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.